Replies to post #338585 on Innovation Pharmaceuticals Inc (IPIX)

[olden_grumpini]

Look at page 18 of the slide deck from the presentation they did at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2015). There you will see that 25 out of 159 patients treated with brilacidin reported hypertension > 160 mmHg.

25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2015): “A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin...

Also note that the most recent trials of brilacidin (the P2 trial for OM and the P1 trial for colonic delivery) excluded patients with hypertension. That's something that wasn't done previously.

From “Exclusion Criteria” of P2 trial for OM:

10. Has untreated hypertension or has hypertension under treatment that meets protocol definitions.

From “Exclusion Criteria” of P1 trial for colonic delivery:

e. Has untreated hypertension or has hypertension under treatment.

In my mind, IPIX knows that hypertension is an issue with brilacidin. Whether it will be an issue with COVID patients depends on the dosages. Based on my reading of the materials and methods in the RBL study I believe that the IC90 dose has the potential to cause hypertension. Since hypertension is often associated with ARDS I think this is something of a red flag.